Montreal, October 10, 2025 – Mila - Quebec Artificial Intelligence Institute, is proud to announce a new partnership with Intrepid Labs, an emerging force at the intersection of AI, automation, and drug development, to help advance Intrepid’s AI-driven robotic drug formulation platform: Valiant™. This platform compresses drug formulation timelines from months to days, delivering optimized solutions with unmatched speed and precision while setting a new standard for how transformative therapies reach patients.
With this partnership, Intrepid Labs joins a network of cutting-edge AI research and innovation, gaining access to new expertise, training, and strategic exchanges. “Becoming part of Mila’s vibrant AI community provides Intrepid Labs with access to additional world-class expertise, collaborative events, and exceptional talent. This connection will help us accelerate innovation in drug formulation and continue to position us at the forefront of the field,” states Christine Allen, CEO of Intrepid Labs.
“Intrepid’s groundbreaking work at the crossroads of AI, robotics, and pharmaceutical science is exactly the kind of bold, cross-disciplinary innovation Mila is proud to champion,” said Stéphane Létourneau, Executive Vice President at Mila. “Through this partnership, we are not only accelerating critical breakthroughs in drug development, but also strengthening our community with fresh opportunities for collaboration, knowledge sharing, and global impact.”
The partnership also promises to further strengthen Mila’s talent base, as Intrepid Labs’ newly appointed Head of Machine Learning, Michael Craig, will represent the company in Montreal, where he will advance Intrepid’s AI initiatives. In this new role, Craig will spearhead the conception, design, and implementation of AI/ML methods to support formulation design, experimentation, and automation in R&D.
“While AI in pharma has largely focused on early discovery and clinical documentation, formulation is an underexplored area and a frequent contributor to clinical trial failure, demanding equal attention,” explains Craig. “By bringing generative and optimization-driven methods to formulation, we can anticipate robust designs earlier, reduce costly setbacks, and meaningfully increase the likelihood that promising therapies reach patients.”
By joining Mila’s diversified community, Intrepid Labs strengthens its position as an emerging leader in AI-driven drug development and formulation science, driven by its mission to accelerate the development and delivery of more effective therapies to patients everywhere.
About Intrepid Labs
Intrepid Labs is redefining drug formulation, a critical step in drug development that determines therapeutic efficacy, safety, and patient experience, through its Valiant™ platform. This AI-driven, robotic lab compresses timelines from months to days, exploring the full formulation design space to deliver optimized, data-driven solutions. Founded by leaders in drug delivery and AI, Intrepid partners with pharmaceutical companies, CROs, CDMOs, and biotechs to accelerate R&D and advance proprietary delivery technologies for licensing. With multiple strategic collaborations and a growing pipeline, Intrepid sets a new standard for excellence in formulation, enabling faster, more precise, and cost-effective paths to transformative therapies. Learn more at intrepidlabs.tech.
About Mila
Founded by Professor Yoshua Bengio of the University of Montreal, Mila is the world’s largest academic research center for deep learning, bringing together over 1,500 specialized researchers in machine learning. Based in Montreal and funded in part by the Government of Canada through the Pan-Canadian AI Strategy, Mila's mission is to be a global center for scientific advancements that inspire innovation and the growth of AI for the benefit of all. Mila is a globally recognized non-profit organization for its significant contributions to deep learning, especially in the fields of language modelling, automatic translation, object recognition, and generative models. For more information, visit mila.quebec.
